Monday, 11 May 2015 10:09

Measuring Circulating Tumor DNA for Recurrence in DLBCL

Written by 
Rate this item
(1 Vote)
Written interview with Dr. Mark Roschewski MD and Dr Wyndham H Wilson MD-PhD from National Cancer Institute. They nvestigated the ability of a blood-based assay to monitor patients with DLBCL during and after their initial therapy. The assay studied amplifies and quantifies small amounts of circulating tumor DNA from the patient
Read 296830 times

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe

WEIGH-IN WEDNESDAY

Do you know the differences between the different phases of clinical trials?

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.